Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


PEPTIDES OF 3 TO 100 AMINO ACID RESIDUES

Subclass of:

530 - Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
530324000 25 or more amino acid residues in defined sequence 170
530317000 Cyclic peptides 87
530322000 Peptides containing saccharide radicals, e.g., bleomycins, etc. 79
530326000 15 to 23 amino acid residues in defined sequence 70
530333000 Synthesis of peptides 65
530345000 Chemical aftertreatment, e.g., acylation, methylation, etc. 56
530344000 Separation or purification 48
530328000 8 to 10 amino acid residues in defined sequence 44
530327000 11 to 14 amino acid residues in defined sequence 40
530331000 Tripeptides, e.g., tripeptide thyroliberin (TRH), melanostatin (MIF), etc. 37
530303000 Insulin; related peptides 31
530330000 4 to 5 amino acid residues in defined sequence 30
530323000 Peptides with at least one nonpeptide bond other than a disulfide bond joining two or more sequences of amino acid residues, e.g., homomeric heterodectic peptide other than cyclic disulfide, depsipeptides, etc. 23
530329000 6 to 7 amino acid residues in defined sequence 23
530308000 Glucagon; related peptides 15
530325000 24 amino acid residues in defined sequence 6
530332000 Containing at least one abnormal peptide link, e.g., gamma peptide bonded, etc. 3
20090221790METHOD FOR STABILIZATION OF PROTEINS USING NON-NATURAL AMINO ACIDS - The present invention provides a method for producing modified stable polypeptides introducing at least one non-natural amino acid into the hydrophobic region of the polypeptide. The thermal and chemical stability of such polypeptides is improved compared to those properties of its corresponding wild type proteins.09-03-2009
20120046445GLUTATHIONE-BASED DELIVERY SYSTEM - A delivery system is provided. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol derivative bonded thereto, and a glutathione (GSH) or a glutathione derivative bonded to the polyethylene glycol or the polyethylene glycol derivative.02-23-2012
20110046348METHODS OF PREPARING PEPTIDE DERIVATIVES - The invention relates to methods of preparing peptide hydrazides useful in as intermediates in preparing derivatized peptides and amenable to conversion to reactive azide comprising species. The invention relates to chemical methods of preparing such species from protected peptide-resins containing the aspartyl or glutamyl residues with orthogonal side-chain carboxylic acid protecting groups ester of Asp and Glu. These esters can be selectively converted to the corresponding side-chain hydrazides useful in various synthetic applications02-24-2011
530311000 Somatostatin (SRIF); related peptides 2
20100160604BOC AND FMOC SOLID PHASE PEPTIDE SYNTHESIS - A solid phase method for synthesizing a peptide containing three or more amino acid residues utilizing both Boc and Fmoc protected amino acids and a chloromethylated polystyrene resin.06-24-2010
20120190814Thiol Protecting Group - The present invention relates to the use of a compound comprising a moiety of formula (I) as a reagent for protecting a thiol group in a thiol compound07-26-2012
530307000 Calcitonin; related peptides 2
20130165624Selective Binding Compounds - Compounds which can include an active (drug) moiety have the general formula (I):06-27-2013
20100240865PROCESS FOR PRODUCTION OF CYCLIC PEPTIDES - The invention relates to methods for the preparation of polypeptides. The polypeptides are prepared in high purity of at least about 98.5%, and preferably at least about 99% by HPLC.09-23-2010
530313000 Lutenizing hormone releasing factor (LRF); related peptides 1
20080306242INTERMEDIATES FOR LHRH ANTAGONIST SYNTHESIS, PROCESS FOR THE PRODUCTION, AND PROCESS FOR LHRH ANTAGONIST PRODUCTION - The peptides Ac-D-2Nal-D-4ClPhe-D-3Pal-OH and Boc-D-2Nal-D-4ClPhe-D-3Pal-OH are intermediates useful in the synthesis of LHRH analogs by coupling with suitable heptapeptides, in particular with the heptapeptides P12-11-2008
530309000 Secretin or gastrin; related peptides 1
20110237774METHOD FOR INTRODUCING DOTA - The invention provides a method for introducing 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (DOTA) into a compound such as a peptide. The method comprises a first step for preparing a mixed liquid of DOTA having no protecting group and dimethylsulfoxide, and a second step for contacting the mixed liquid with the compound carried on a solid-phase carrier.09-29-2011
530315000 Oxytocin; vasopressin; related peptides 1
20090318665PHARMACEUTICAL FORMULATIONS - Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.12-24-2009
Entries
DocumentTitleDate
20130046076Crystal Structure of Amino Terminal Portion of Influenza Virus Polymerase PA Subunit and Use thereof - Present invention disclosed three-dimensional crystal structure of N-terminus polypeptide of influenza virus polymerase subunit (PA_N). PA_N is residues 1˜50 to 150˜300 of influenza virus polymerase subunit PA. In three-dimensional structure, at least 40% of atoms showed same atomic coordinates, compared to that listed in Table. In other words, in three-dimensional structure of influenza virus polymerase subunit PA_N, 40% of atomic coordinates on carbon skeleton of residues of influenza virus polymerase subunit PA_N, showed less than or equal to 1.7 Å of average variance, compared to the atomic coordinates listed in Table1. Present invention also disclosed the expression, purification, crystallization methods, and three-dimensional crystal structure of 256 residues in the N-terminus of influenza virus polymerase subunit PA, and applications of the crystal structure on drug screening and designing.02-21-2013
20100160602METHOD FOR PREDICTING PROTEIN AGGREGATION AND DESIGNING AGGREGATION INHIBITORS - The present invention provides methods of predicting protein aggregation and designing aggregation inhibitors. One such method for predicting potential protein aggregation inhibiting peptide sequences, includes the steps of: a) identifying a peptide sequence forming at least part of an aggregation region in a target protein; b) testing whether said peptide sequence forms part of a β-sheet; c) if a positive result is achieved in step b), extracting the adjacent strands of that sheet; d) identifying residues in the adjacent strands to said peptide sequence whose side chains interact with said peptide sequence, those residues forming a potential protein aggregation inhibiting peptide sequence. The present invention also provides methods of designing compounds using the residues identified in the above method; compounds produced by the methods and computer programs for carrying out the above methods.06-24-2010
20110196127POLY-BETA-PEPTIDES FROM FUNCTIONALIZED BETA-LACTAM MONOMERS AND ANTIBACTERIAL COMPOSITIONS CONTAINING SAME - Disclosed is a method of making β-polypeptides. The method includes polymerizing β-lactam-containing monomers in the presence of a base initiator and a co-initiator which is not a metal-containing molecule to yield the product β-polypeptides. Specifically disclosed are methods wherein the base initiator is potassium t-butoxide, lithium bis(trimethylsilyl)amide (LiN(TMS)08-11-2011
20130085259METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS - The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.04-04-2013
20090111968Self-assembled proteins and related methods and protein structures - The present invention provides user-directed construction of novel specific homo- and hetero-dimeric, and multimeric assemblages of proteins. The present invention is comprised of gene sequences that transcribe peptide sequences that form links between proteins, where the peptide sequences produce a hook or loop which supports specific self-assembly of homo-dimers, hetero-dimers and multimers of the proteins to which they are attached. The hook or loop may have a short aliphatic repeat sequence and a metal binding loop. The present invention also provides a method of constructing a hook motif of metal binding loop sequences that may be attached to at least one aliphatic repeat sequence to produce the assemblages of proteins. Also provided are protein structures produced by the methods of the present invention.04-30-2009
20100041867REVERSIBLE PEGYLATED DRUGS - Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.02-18-2010
20100041866Solid Support Reagents for Synthesis - A compound which can be attached to a solid support and used as a reagent for methods of solid phase synthesis has the following structure: (I) where Ri is selected from hydrogen and C02-18-2010
20130072657CELL GROWTH INHIBITOR DERIVED FROM p16INK4a AND METHOD OF SYNTHESIZING THE SAME - The various embodiments herein provide a cell growth inhibitor derived from p1603-21-2013
20130060003CHEMICAL PREPARATION OF POLYUBIQUITIN CHAINS - The present invention discloses a process for the preparation of a Poly-ubiquitin chain, this process comprising ligating a Ubiquitin thioester Ubm-SR with a Ubiquitin Ubq. Further are disclosed poly-ubiquitin chains prepared according to this process, in particular poly-ubiquitin chains containing at least one unnatural amino acid.03-07-2013
20130066046General Method for Generating Ultra-High Affinity Binding Proteins - A method for combining two or more maximum moieties to yield functional cassettes with ultra-high binding affinities, in which at least two binding sequences are incorporated into the same linear polypeptide such that each is separated by between five and forty amino acids, to create a polypeptide having geometrically increased binding affinity compared to the arithmetically summed binding affinities of the individual maximum moieties.03-14-2013
20080293915Nanoscale Neuromodulating Platform For Retina Neuron Activation Apparatus and Method - Postsynaptic membrance receptor proteins of retinal neurons proximal to the rods and cones mediate the transmission of visual signals at multiple types of chemical synapses in the normally functioning retina, and there is reason to believe that these proximal retinal neurons in certain cases remain functional despite the disease-induced loss of rod and cone visual signaling. The invention is a nanoscale molecular structure that can selectively attach to the extracellular face of specific membrane receptors of post-photoreceptor retinal neurons and, by modulating the postsynaptic receptor's activity in response to light, restore visual signaling in retina damaged by photoreceptor degenerative disease.11-27-2008
20090247731BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES - Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.10-01-2009
20100036088Selective poly-N-substituted glycine antibiotics - Antimicrobial peptoid compounds and related compositions as can be used against bacteria effectively and selectively.02-11-2010
20100249369Production and use of highly functional, highly branched or hyperbranched polylysines - The present invention relates to new high-functionality, highly branched or hyperbranched polylysines, to processes for preparing them, and to their use.09-30-2010
20100137557USE OF ONE OR MORE METAL CARRIERS TO SELECTIVELY KILL MAMMALIAN CELLS - Compositions and methods for decreasing the viability of cells, particularly aberrant non-healthy cells, and most particularly cancer cells, are disclosed. The primary agent that causes cell death is a toxic metal atom or ion. Embodiments of the invention provide compositions and methods to ensure that the toxic metal is directed to the desired cell or tissue. In one embodiment, the metal is bound to a sulfur-rich peptide or protein carrier containing a targeting moiety. Such metal-protein complex is targeted to the selected cells or tissues to enrich the cell or tissue site with the metal-containing peptide or protein molecules followed by administering a dithiocarbonyl which carries the metal from the protein inside the cells to induce cell death.06-03-2010
20120108787Immobilization Particles for Removal of Microorganisms and/or Chemicals - An immobilization particle for immobilizing a target microorganism or target chemical found in or on a mammal that includes: immobilization molecules capable of attaching to a target microorganism or a target chemical, which immobilization molecules are attached to one or more portions of a substrate structure; wherein the substrate structure is capable of inhibiting contact between tissues of the mammal and target microorganisms or target chemicals attached to immobilization molecules attached to the one or more portions.05-03-2012
20080207873Biosynethetic gene cluster for jerangolids - Domains of jerangolid polyketide synthase and modification enzymes and polynucleotides encoding them are provided. Methods to prepare jerangolid in pharmaceutically useful quantities are described, as are methods to prepare jerangolid analogs and other polyketides using the polynucleotides encoding jerangolid synthase domains or modifying enzymes.08-28-2008
20120296067COMPOUND CAPABLE OF BINDING TO NATURALLY OCCURRING DENATURED PROTEIN, AND METHOD FOR SCREENING FOR THE COMPOUND - Screening for low molecular weight compounds that regulate protein-protein interactions of a large number of proteins, including transcription factors, that have disordered sequences has been performed, but it has been almost impossible to obtain low molecular weight compounds having sufficient activity. The present inventors found that, regarding screening for a protein that regulates an interaction between an intrinsically disordered protein and a partner protein, carrying out screening while focusing on an disordered sequence, and selecting a candidate compound from peptidomimetic compounds that have a peptidomimetic backbone and have a peptide side chain or a side chain similar thereto enable a compound that regulates the activity of an intrinsically disordered protein to be efficiently selected, and the present inventors accomplished the present invention.11-22-2012
20080287648Method for Solid Phase Peptide Synthesis - A novel method for synthesizing a Hirulog peptide is devised.11-20-2008
20120142891FUSION PROTEIN SYSTEMS SUITABLE FOR HIGH EXPRESSION OF PEPTIDES - The present invention discloses an improved process for the production of desired recombinant peptides from bacterial cells by using G-CSF as a novel fusion partner for their high level expression in these cells. The invention further provides an expression system comprising the fusion protein wherein the G-CSF is operatively linked to the peptide of interest via an enzymatic or chemical cleavage site which can be used to separate the fusion partner from the said peptide.06-07-2012
20120142890Biosynthetic Polypeptide Fusion Inhibitors - Modified biosynthetic polypeptide fusion inhibitors, methods for manufacturing, and uses thereof are provided.06-07-2012
20090023892Enzymatic reactions in the presence of keto acids - Conversion in vitro of X-Gly to X-alpha-hydroxy-Gly or X-NH01-22-2009
20110230637MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN - Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.09-22-2011
20090192289OMI PDZ MODULATORS - The invention provides modulators of Omi PDZ-ligand interaction, and methods of identifying and using these modulators.07-30-2009
20110224404METHOD FOR DEVELOPMENT OF A PEPTIDE BUILDING BLOCK USEFUL FOR DE NOVO PROTEIN DESIGN - The present invention relates to a top-down symmetric deconstruction approach which provides a novel alternative means to successfully identify a useful polypeptide “building block” for subsequent “bottom-up” de novo design of target protein architecture. The present invention also pertains to a novel peptides isolated by top-down symmetric deconstruction which may be useful for design or directed evolution of novel proteins with novel functionalities.09-15-2011
20080262197METHODS AND MATERIALS FOR TREATING INFLAMMATORY CONDITIONS - The invention provides methods and materials for treating inflammatory conditions. Specifically, the invention provides polypeptides, isolated nucleic acids, host cells, and methods that can be used to induce an antibody response in a mammal against an antigen such as C5 or C5a. For example, the methods and materials described herein can be used to reduce the effects of C5a within a mammal by reducing the amount of total and receptor bound C5a in the mammal.10-23-2008
20100160603METHOD FOR ALTERING MORPHOLOGY OF BLOCK COPOLYMER - The invention provides a pharmaceutical formulation comprising drug-encapsulated polymer micelles formed from a block copolymer having a hydrophilic segment and hydrophobic segment, and has been subjected to high-pressure treatment. The invention also provides a treatment method for a block copolymer having a hydrophilic segment and a hydrophobic segment for formation of drug-encapsulated polymer micelles, the treatment method comprises a step of subjecting the block copolymer to high-pressure treatment.06-24-2010
20110060120IMMUNOGENIC TREATMENT OF CANCER BY PEPTIDES INDUCING THE PLASMA MEMBRANE EXPOSURE OF ERP57 - We have recently identified (a) ectocalreticulin as the main source of immunogenicity of cancer cell death induced by chemotherapy or radiotherapy, (b) ectoERP57 as critical protein for inducing cell surface exposure of calreticulin, and (c) that ectoERP57 and ectocalreticulin are cotranslocated together to the tumor cell surface by the mediator of the inhibition of PP1/GADD34 complex. Here, I show the design of a peptide that inhibits the interaction between PP1 and GADD34 complex. These inhibitor peptide (a) induce ectocalreticulin and ectoERP57 in a variety of tumor cell lines by the mediator of the inhibition of the interaction between PP1 and GADD34, (b) increase the phagocytosis of anticancer targeted proapoptotic peptide and chemotherapy-treated tumor cells by dendritic cells, and (c) improve highly the anticancer activity of proapoptotic peptides and chemotherapy by suppressing or reducing the tumor growth in several isogenic mouse models of colon, mammary, and fibrosarcoma tumors and by increasing the lifespan of transgenic adenocarcinoma mouse prostate mice. These results suggest that these targeted peptides combination approach could serve as a new powerful autonomous anticancer therapy.03-10-2011
20120197003Modified oligopeptides for the treatment of pancreatitis, stomach ulcers, and other hyperenzymemias based on enzyme peptide inhibitors and methods for obtaining them - Modified oligopeptides for the treatment of pancreatitis, stomach ulcers, and other hyperenzymemias based on an enzyme peptide inhibitor where in the capacity of the main active ingredient, a mixture (assembly) of chemically modified oligopeptides are used that are products of autological hydrolysis of the same proteolytic enzymes of trypsin, chymotrypsin, and papain, with changes of their molecular charges to the opposite through acylation with succinic anhydride and alkylation by monochloracetic acid.08-02-2012
20120197004NOVEL ANTI-MICROBIAL PEPTIDOMIMETIC COMPOUNDS AND METHODS TO CALCULATE ANTI-MICROBIAL ACTIVITY - This invention encompasses synthetic antimicrobial peptide analogs having certain un-natural amino acids, including the un-natural amino acids hydrophobic tetrahydroisoquinolinecarboxylic acid (Tic) and octahydroindolecarboxylic acid (Oic), incorporated into the polypeptide backbone. These antimicrobial peptides (AMPs) are useful to treat infection in humans and other mammals of such bacteria as Gram positive bacteria, Gram negative bacteria and 08-02-2012
20100152418Switch-Peptides as Tool for the Study of Fibrillogenesis - The present invention relates to a method for the manufacture of a peptidic folding precursor (Switch-Peptide) stable and soluble at physiological conditions, derived from a peptide having a potential for self-assembling and fibrillogenesis. Another object of the invention is to provide a tool for the quantitative, controlled in vitro study of fibrillogenesis and its inhibition of peptides involved in degenerative diseases.06-17-2010
20100152417Fluorescent Amino Acid Derivatives - The subject of the present invention is to provide a fluorescent substance excitable under visible light, having higher photostability and a long fluorescence lifetime. Another subject is to provide a fluorescent substance consists of a non-natural amino acid applicable to peptide synthesis systems.06-17-2010
20090036647BITORAN WHICH IS TRYPSIN-INHIBITOR-LIKE PROTEIN DERIVED FROM BITIS ARIETANS VENOM, AND USE THEREOF AS BLOOD COAGULATION FACTOR Xa INHIBITOR - The present invention provides a novel Kunitz-type inhibitor protein exhibiting high potency to inhibit serine protease activity of human blood coagulation factor Xa. The Kunitz-type inhibitor protein against human blood coagulation factor Xa according to the present invention is 02-05-2009
20110046343Primer Array Synthesis and Validation - Methods are presented for generating large sets for polymers. The methods employ high density oligonucleotide array.02-24-2011
20110046344PARALLEL PREPARATION OF HIGH FIDELITY PROBES IN AN ARRAY FORMAT - The present invention provides massively parallel oligonucleotide synthesis and purification for applications that utilize large collections of defined high-fidelity oligonucleotides (e.g., from about 1002-24-2011
20110046342TUMOR SUPPRESSOR ACTIVATING POLYPEPTIDES AND USES THEREOF - Chimeric tumor suppressor activating peptides derived from matrix attachment region binding protein (MARBP) SMARI unique in their sequence comprising a arginine rich motif flanked by serine residues wherein from the stretch of four consecutive serine residues the first serine residue gets phosphorylated by the protein kinase C family of serine threonine kinases being indispensable for its functionality, the phosphorylation being directly correlated to the phosphorylation of p53 at serine 15 residue thereby stabilizing it, wherein the peptide activates p53 by modifying it post translationally which allow phosphorylation and translocation of p53 to the nucleus.02-24-2011
20110245458PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS - Disclosed is a peptide nucleic acid monomer as well as a corresponding peptide nucleic acid molecule. The monomer comprises a terminal amino group and a terminal group A. The terminal amino group and the terminal group A are connected by an aliphatic moiety. The main chain of this aliphatic moiety is free of groups that are charged under physiological conditions. The terminal group A is one of —COOH, —COOR10-06-2011
20100056754NANO-PUMP USING MOLECULAR MOTOR - Nano-pumps including nano-motors that move dynamically in response to exterior stimuli, for example in response to photonic energy, electrical energy, a magnetic field, and/or a chemical concentration. The motion of such a molecular sized nano-motor structure can be managed and controlled so as to act as a pump. Such pumps could be used in nanobots in order to perform work.03-04-2010
20080214781LEUCINE-BASED MOTIF AND CLOSTRIDIAL NEUROTOXINS - Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, preferably the biological half-life, of the modified neurotoxin relative to an identical neurotoxin without the structural modification. The structural modification includes addition or deletion of a leucine-based motif or parts thereof. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat biological disorders include treating autonomic disorders, neuromuscular disorders or pains.09-04-2008
20110028685Analyte Determination Utilizing Mass Tagging Reagents Comprising A Non-Encoded Detectable Label - This invention pertains to methods, mixtures, kits and compositions pertaining to analyte determination and/or quantification by mass spectrometry using compounds comprising a reporter moiety and a non-encoded detectable label. The compounds can be used in sets for the analysis of mixtures of labeled analytes.02-03-2011
20100179303SITE-SPECIFIC CONJUGATION OF LIGANDS TO NANOPARTICLES - A new radioconjugate NP has been developed using recombinant antibody fragments, di-scFv-c (111 In-DOTA-di-scFv-NP) for imaging and therapy of anti MUC-1 10 expressing cancers since aberrant MUC-1 Is abundantly expressed on the majority of human epithelial cancers. Selection and engineering of anti-MUC-1 di-scFv-c (50 kDa) was generated to link NP-M (maleimide). DOTA chelate was conjugated with di-scFv-c for the radiometal chelation to trace the RINP at in vivo. This RINP preparation can provide uniquely high tumor cell binding NP for AMF driven tumor hyperthermia.07-15-2010
20110082279Chemiluminescent Compounds - The invention relates to chemiluminescent compounds of general formula (I)04-07-2011
20110190472TRANSFECTION VECTOR - The present invention relates to a novel secretory signal, a novel plasmid containing the secretory signal, a transformed anaerobic bacterium transformed with said plasmid, a gene transfer carrier consisting of said anaerobic bacterium, and a pharmaceutical composition containing said carrier.08-04-2011
20100029902COATED NANOPARTICLES AND METHOD FOR COATING NANOPARTICLES - Provided are coated nanoparticles and a method for coating nanoparticles. The coated nanoparticles are coated with proteins to prevent aggregation of the coated nanoparticles. The method for coating nanoparticles may include mixing an excessive amount of proteins with the nanoparticles. Alternatively, the method for coating nanoparticles may include coating with first proteins, treating with ultrasonic waves, and coating with second proteins.02-04-2010
20100016545PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT - The present invention relates to a process for linking two molecules by means of a Diels Alder reaction with inverse electron requirement (DARinv), comprising the following steps: reaction of a (a) triazine or tetrazine with one or more electron-attracting substituents on the ring as a diene component, the electron-attracting substituents being selected from: 01-21-2010
20090093612AMIDE-SUBSTITUTED XANTHENE DYES - The present invention provides amide-substituted xanthene fluorescent dyes and reagent for the introduction of phosphonate or sulfo groups into the fluorescent dyes.04-09-2009
20110071273CHIMERIC ANTIGEN-SPECIFIC T CELL-ACTIVATING POLYPEPTIDES - The invention provides an immunogenic or antigenic polypeptide containing a translocation domain, a peptide epitope, at least one biologically active agent, and cleavage sites. These polypeptides are useful for activating T cell responses.03-24-2011
20120041171PROCESS FOR THE PRODUCTION OF A RECOMBINANT POLYPEPTIDE OF INTEREST - The present invention relates to a process for the production of a recombinant polypeptide of interest, a polypeptide obtained by said process, a recombinant polynucleotide, an expression vector, an expression construct and to the use of a specific signal peptide and of a polynucleotide encoding said specific signal peptide for the production of a recombinant polypeptide of interest.02-16-2012
20120046441Combinatorial Synthesis of Libraries of Macrocyclic Compounds Useful in Drug Discovery - A library of macrocyclic compounds of the formula (I)02-23-2012
20090259018PROTEIN CONSENTRATE FROM STARCH CONTAINING GRAINS: COMPOSITION, METHOD OF MAKING, AND USES THEREOF - The present invention relates to methods of producing a protein concentrate from a starch containing grain and uses thereof. In an exemplary embodiment, the protein concentrate produced is used to prepare an aquaculture feed.10-15-2009
20120010384EPITOPE SYNCHRONIZATION IN ANTIGEN PRESENTING CELLS - Disclosed herein are vaccines and methods for inducing an immune response against cancer cells and cells infected with intracellular parasites. Vaccines having housekeeping epitopes are disclosed. The housekeeping epitope is formed by housekeeping proteasomes in peripheral cells, but not by professional antigen presenting cells. A vaccine containing a housekeeping epitope that is derived from an antigen associated with a peripheral target cell can thus direct an immune response against the target cell. Methods of treatment are also disclosed, which involve administering a vaccine having a housekeeping epitope.01-12-2012
20120309934INTRACELLUAR TARGETING BIPODAL PEPTIDE BINDER - An intracellular targeting bipodal-peptide binder specifically binding to an intracellular target molecule, comprising: (a) a structure-stabilizing region comprising a parallel amino acid strand, an antiparallel amino acid strand or parallel and antiparallel amino acid strands to induce interstrand non-covalent bonds; (b) target binding regions I and II each binding to each of both termini of the structure-stabilizing region, wherein the number of amino acid residues of the target binding region I is n and the number of amino acid residues of the target binding region II is m; and (c) a cell-penetrating peptide (CPP) linked to the structure-stabilizing region, the target binding region I or the target binding region II. Also contemplated is a method for preparing an intracellular targeting bipodal-peptide binder. The bipodal-peptide binder capable of binding to intracellular targets has applications to drugs, in vivo molecular imaging, in vitro cell imaging, drug delivery targeting and escort molecules.12-06-2012
20110092668AZIDE FUNCTIONALIZED PEPTIDE TARGETING GROUPS - The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.04-21-2011
20110028686Protein binding miniature proteins - The present invention provides a protein scaffold, such as an avian pancreatic polypeptide, that can be modified by substitution of two or more amino acid residues that are exposed on the alpha helix domain of the polypeptide when the polypeptide is in a tertiary form.02-03-2011
20110105718NEL-RELATED PROTEIN TYPE 1 ANTIBODY - The present invention provides novel human genes, for example a novel human gene comprising a nucleotide sequence coding for the amino acid sequence shown under SEQ ID NO:1. The use of the genes makes it possible to detect the expression of the same in various tissues, analyze their structures and functions, and produce the human proteins encoded by the genes by the technology of genetic engineering. Through these, it becomes possible to analyze the corresponding expression products, elucidate the pathology of diseases associated with the genes, for example hereditary diseases and cancer, and diagnose and treat such diseases.05-05-2011
20100093973POLY(AMINO ACID) COMPOUND HAVING INHIBITORY ACTIVITY ON ABSORPTION OF PHOSPHORUS AND PHOSPHORUS ABSORPTION INHIBITOR - Herein disclosed is a water-soluble compound represented by the following general formula (I) or a salt thereof. The compound is a novel water-soluble compound having an inhibitory effect on the absorption of phosphorus in vivo.04-15-2010
20120123088ADDITIVE FOR THE CRYSTALLIZATION OF PROTEINS, USE AND PROCESS - The present invention relates to the use and to a process involving at least one calix[n]arene derivative substituted by at least one acid functional group on the upper face and at least one aliphatic chain of variable length on the other face, as an additive for crystallization of a polar and/or positively charged molecule. The use and the process of the present invention have the advantage of enabling, facilitating and/or accelerating the crystallization of polar and/or positively charged molecules, especially of membrane proteins that are in solution or soluble, which had previously proved to be very difficult.05-17-2012
20110184145METHOD OF ADMINISTERING THERAPEUTIC POLYPEPTIDES, AND POLYPEPTIDES THEREFOR - The invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules.07-28-2011
20100204443VAPOR DEPOSITION OF BIOMOLECULES - A coating method is disclosed. The coating method comprises placing a substrate and a biomolecule in a chamber and applying a vapor deposition process within the chamber so as to form a solid deposition of the biomolecule on at least a portion of a surface of the substrate.08-12-2010
20100204442Luminescent lanthanide (III) chelates, chelating agents and conjugates derived thereof - This invention relates to a group of novel chelating agents, novel chelates, biomolecules labeled with said chelates or chelating agents as well as solid supports conjugated with said chelates, chelating agents or labeled biomolecules. Especially the invention relates to novel chelating agents useful in solid phase synthesis of oligonucleotides or oligopeptides and the oligonucleotides and oligopeptides so obtained.08-12-2010
20120172575ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS - 1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate.07-05-2012
20120220751Non-Fluorescent Quencher Compounds and Biomolecular Assays - Bis-diazo, triaryl and aryldiazo-N-arylphenazonium quencher moieties, substituted with electron-withdrawing and electron-donating substituents which induce polarity in the delocalized aryl/diazo ring systems, are useful as labels when attached to biomolecules such as polynucleotides, nucleosides, nucleotides and polypeptides. The quencher moieties are non-fluorescent and accept energy transfer from fluorescent reporter labels by any energy-transfer mechanism, such as FRET.08-30-2012
20120322975NUCLEIC ACIDS ENCODING ANTIBODIES THAT BIND FACTOR D - The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)12-20-2012
20120322974ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS - 1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate.12-20-2012
20100234562ACUTE LEUKEMIA AND LYMPHOBLASTIC LYMPHONA-SPECIFIC CD43 EPITOPE AND USE THEREOF - The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma.09-16-2010
20120149867Method For Processing Crustaceans And Products Thereof - The present invention contemplates the creation of a low fluoride oil processed from a phospholipid-protein complex (PPC) formed immediately upon a crustacean (i.e., for example, krill) catch. The process comprises disintegrating the crustaceans into smaller particles, adding water, heating the result, adding enzyme(s) to hydrolyze the disintegrated material, deactivating the enzyme(s), removing solids from the enzymatically processed material to reduce fluoride content of the material, separating and drying the PPC material. Then, using extraction with supercritical CO06-14-2012
20110160430FLUORINE-LABELED COMPOUNDS - Methods for introducing fluorine atom onto a polypeptide are provided. Also provided are linkers, bioconjugates, and bifunctional compound agents made using the methods, linkers, and bioconjugates. The methods comprise: (i) providing a linker comprising a thiol-reactive terminus and an aldehyde-reactive terminus; (ii) reacting the thiol-reactive terminus of the linker with a polypeptide comprising at least one thiol group or a reactive derivative thereof; and (iii) subsequently reacting the aldehyde-reactive terminus of the linker with a fluorine-substituted aldehyde.06-30-2011
20080242834Methods of Predicting Hyp-Glycosylation Sites For Proteins Expressed and Secreted in Plant Cells, and Related Methods and Products - Proteins with Hyp-glycosylation are more likely to be secreted in plant cells at high levels than those without. Methods are disclosed for the prediction of Pro-hydroxylation and Hyp-glycosylationsites in proteins. Such methods can be used to identify (1) proteins which, without modification, are predisposed to develop Hyp-glycosylation, if expressed in plant cells, and (2) modifications (especially substitution mutations) which increase the propensity of a protein to develop Hyp-glycosylation, with a view to high level or increased secretion. It is also possible to determine empirically whether a particular protein will undergo Hyp-glycosylation suitable for the desired level of secretion in plant cells. Both modified proteins, and methods for the expression and secretion of predisposed and modified proteins, are claimed.10-02-2008
20120253006TWO HELIX BINDERS - Provided herein are isolated polypeptides derived from the staphylococcal protein A protein B domain comprising a pair of anti-parallel alpha helices that are capable of binding a target. Also provided are nucleic acid sequences encoding such two helix binders, vectors containing the nucleic acid sequences encoding for two helix binders, and host cells transformed with vectors containing the nucleic acid sequences encoding for the two-helix binders. Also provided are methods of using the two helix binders.10-04-2012
20080200646PREVENTION AND REDUCTION OF BLOOD LOSS - Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.08-21-2008
20080200645Methods for Treatment or Prophylaxis of Atherosclerosis and Reperfusion Injury - The invention provides the use of a complement inhibitor in the preparation of a medicament for the treatment or prophylaxis of atherosclerosis in a subject in need of treatment by administering to the subject a therapeutically effective amount of said medicament. The complement inhibitor may be a molecule which can inhibit activation of at least one complement component, inhibit activity of at least one activated complement component, act as an antagonist against at least one complement receptor, or combinations thereof.08-21-2008
20080200644Method for inverse solid phase synthesis of peptides - The present invention provides a process for preparing a peptide of formula (I):08-21-2008
20090264616Cyclodipeptide Synthetases and Their Use for Synthesis of Cyclo(Leu-Leu) Cyclodipeptide - Isolated, natural or synthetic polynucleotides and the polypeptides encoded by said polynucleotides, that are involved in the synthesis of cyclodipeptides, the recombinant vectors comprising said polynucleotides or any substantially homologous polynucleotides, the host cell modified with said polynucleotides or said recombinant vectors and also methods for in vitro and in vivo synthesizing cyclo(Leu-Leu) cyclodipeptide and its derivatives and applications thereof.10-22-2009
20100286362Mammalian MDM2 Binding Proteins and Uses Thereof - Isolated nucleic acid sequences encoding mammalian MDM11-11-2010
20130137849DIPEPTIDE LINKED MEDICINAL AGENTS - A non-enzymatically self cleaving dipeptide element is provided that can be linked to known medicinal agents via an amide bond. The dipeptide will spontaneously be cleaved from the medicinal agent under physiological conditions through a reaction driven by chemical instability. Accordingly, the dipeptide element provides a means of linking various compounds to known medicinal agents wherein the compounds are subsequently released from the medicinal agent after a predetermined time of exposure to physiological conditions. For example, the dipeptide can be linked to an active site of a drug to form a prodrug and/or the dipeptide may comprise a depot polymer to sequester an injectable composition comprising the complex at the point of administration.05-30-2013
20120283409COMPUTATIONALLY DESIGNED INHIBITORS OF AMYLOIDOSIS - Embodiments of the present invention include methods and systems for designing inhibitors of amyloidosis in humans, domesticated animals, and wild animals as well as inhibitors of amyloidosis designed by the methods and systems. Methods and systems for designing inhibitors of amyloidosis are largely computational, in nature, and are directed to designing various types of polymers, small-molecule organic compounds, organometallic compounds, or non-chemical physical processes that can target the extended-α-strand and α-sheet regions of amyloidogenic protein and polypeptide intermediates in order to prevent aggregation of those intermediates into protofibrils and fibrils that, in turn, recruit additional native-conformation proteins and polypeptides into amyloidogenic intermediates and that additionally aggregate to form higher-order structures, such as plaques observed in the brains of patients suffering from the various spongiform encephalopathies.11-08-2012
20120283408FUSION PROTEIN BINDING SPECIFICALLY TO CONSTANT REGION OF ANTIBODY, METHOD OF PREPARING THE FUSION PROTEIN, AND METHOD OF ISOLATING ANTIBODY USING THE FUSION PROTEIN - A fusion protein that includes a polypeptide binding specifically to a constant region of an antibody and a stabilization protein linked to a terminus of the polypeptide, a polynucleotide encoding the fusion protein, a cell including the polynucleotide, a method of preparing the fusion protein, and a method of isolating an antibody by using the fusion protein.11-08-2012
20110313129LARGE STOKES SHIFT DYES - Provided herein are heptamethine cyanine dyes having a large Stokes shift, and the salts and conjugates thereof. Also provided are methods of using and making such large Stokes shift dyes as fluorescence resonance energy transfer (FRET) acceptors or donors.12-22-2011
20090240026Novel Fluorescent Amino Acid Derivative and Production Method Of The Same - An object of the present invention is to provide a novel fluorescent amino acid derivative which can be synthesized by simple steps, can be excited particularly by a blue laser ray region of visible light, and has an improved light stability. Another object is to provide a production method of the fluorescent amino acid derivative. These objects can be achieved by a fluorescent amino acid derivative which is an acridone derivative substituted with an amino acid to comprise an electrophilic substituent group between the amino acid and the acridone derivative. Instead of a conventional strategy that aminophenylalanine is used as a starting material to form a fluorescent group through a coupling reaction and an intramolecular cyclization reaction, a fluorescent acridone derivative is used as a starting material to furnish the material to a reactive group by a position-specific electrophilic substitution reaction, and then the acridone derivative having the reactive group is allowed to couple with an amino acid derivative.09-24-2009
20130203959NONNATURAL COLLAGEN-LIKE PROTEIN AND USE THEREOF - This present invention relates to compositions comprising biological active proteins fused with extended recombinant gelatin-like protein (GLK), nucleic acids encoding the compositions and vectors containing the same, approaches involved in the preparation of the compositions and their pharmaceutical application in the treatment or prevention of diseases.08-08-2013
20130203960MCR DENDRIMERS - The invention relates to a method for producing peptoidic, peptidic and chimeric peptidic-peptoidic dendrimers by multiple iterative multi-component reactions (MCR), in particular Ugi or Passerini multi-component reactions, to compounds produced in this way and to the use thereof.08-08-2013
20120095186POLYION COMPLEX COMPRISING HYDROPHOBIZED POLYAMINO ACID AND USE OF THE SAME - A polyion complex (PIC) or a PIC nanoparticle that may be easily prepared, and that is finally disappeared in vivo due to its suitable biodegradability while exhibiting high stability in vivo, an immunotherapy agent comprising the PIC nanoparticle to which various antigen proteins or peptides may be easily conjugated or incorporated and/or which may be easily mixed with the antigen proteins or peptides, as well as a process for preparing thereof are provided. Specifically, a polyion complex (PIC) comprising a hydrophobized poly(acidic amino acid) and a basic polypeptide, a nanoparticle thereof having a particle shape, an immunotherapy agent comprising the PIC nanoparticle, as well as a process for preparing the PIC, comprising steps of introducing a hydrophobic amino acid to a poly(acidic amino acid) to prepare a hydrophobized poly(acidic amino acid), and dissolving the hydrophobized poly(acidic amino acid) prepared to a buffer, and it is mixed with a basic polypeptide dissolved in a buffer.04-19-2012
20120095185PROCESS FOR CHELATING COPPER IONS USING CB-TE2A BIFUNCTIONAL CHELATE - An isolated conformational isomer of a bifunctional chelating agent of the formula (I):04-19-2012
20130211043METHOD FOR PREVENTING HIV-1 INFECTION OF CD4+ CELLS - This invention provides methods for inhibiting fusion of HIV-1 to CD408-15-2013

Patent applications in class PEPTIDES OF 3 TO 100 AMINO ACID RESIDUES

Patent applications in all subclasses PEPTIDES OF 3 TO 100 AMINO ACID RESIDUES